지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
Background: Most major clinical trials have failed during the last 2 decades, including large clinical trials of secondary prevention and neuroprotection. These results suggest the presence of heterogeneity among stroke patients. Biomarker is defi ned as a biological molecules found in blood, other body fl uids or tissues that is evaluated as an indicator of normal biological processes,pathogenic processes, or pharmacologic responses to a therapeutic intervention. Stroke biomarkers may provide the information on the heterogeneity among patients with ischemic cerebrovascular disease. In addition, stroke biomarkers could be a guiding tool for more effective personalized therapy. Main contents: Three aspects of stroke biomarkers are discussed. First, the role of biomarkers in stroke patients is presented. Second, limitations of current biomarkers (especially protein biomarkers) in the stroke fi eld are discussed with possible reasons. Lastly, types of biomarkers, including protein, genetic and microparticles, are presented with their advantages and disadvantages focusing on the importance of comprehensive approaches using various types of biomarkers. Expectations: Although biomarkers are not recommended as a routine practice in stroke patients, there have been numerous effects to overcome current limitations. The studies reviewed herein suggest that using various biomarkers to improve the understanding of individual pathophysiologies will further promote the development of screening tool of highrisk patients, predicting model of stroke outcome and rational stroke therapy tailored to the specifi cs of each case. (Korean J Stroke 2011;13:57-62)
목차
등록된 정보가 없습니다.
참고문헌 (22)
참고문헌 신청
Arenillas JF / 2008 /
Bang OY / 2005 / Infl ammatory markers, rather than conventional risk factors, are different between carotid and mca atherosclerosis / J Neurol Neurosurg Psychiatry 76 : 112
Barseghian A / 2011 / Adiponectin and vulnerable atherosclerotic plaques / J Am Coll Cardiol 57 : 761 ~ 770
Bhatt DL / 2006 / Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events / N Engl J Med 354 : 1706 ~ 1717
Castellanos M / 2007 / Serum cellular fi bronectin and matrix metalloproteinase- 9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic thera
Bang OY / 2005 / Infl ammatory markers, rather than conventional risk factors, are different between carotid and mca atherosclerosis / J Neurol Neurosurg Psychiatry 76 : 112
Barseghian A / 2011 / Adiponectin and vulnerable atherosclerotic plaques / J Am Coll Cardiol 57 : 761 ~ 770
Bhatt DL / 2006 / Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events / N Engl J Med 354 : 1706 ~ 1717
Castellanos M / 2007 / Serum cellular fi bronectin and matrix metalloproteinase- 9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic thera
이 논문의 저자 정보
최근 본 자료
댓글(0)
0